updated 3/11/2011 7:16:29 AM ET 2011-03-11T12:16:29

DALLAS, March 11, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Cell Therapeutics Inc. (Nasdaq:CTIC). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/CTIC

Cell Therapeutics Inc. (CTIC) engages in the development, acquisition and commercialization of novel treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat cancer. The Company is focused on developing pixantrone, OPAXIO, brostallicin and bisplantinates. Pixantrone is an anthracycline derivative, for the treatment of non-Hodgkin's lymphoma (NHL), and various other hematologic malignancies, solid tumors and immunological disorders. The Company is developing OPAXIO (paclitaxel poliglumex), a maintenance therapy for women with advanced stage ovarian cancer. Brostallicin is a synthetic Deoxyribonucleic Acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity.

For only $39 a month, you can sign up for our real-time stock alert service.  Click here to join now:   http://www.pennystocklive.com/join-premium-membership/

In the report, the analyst notes:

"Following discussions with the FDA's Division of Hematologic Products (DHP), CTIC announced the final clinical trial design of a randomized pivotal trial of its lead drug candidate pixantrone for the treatment of diffuse large B-cell lymphoma (DLBCL).

"It was reported last week that the Company met with officials of the FDA's Office of New Drugs (OND) in Maryland and presented its arguments supporting the Company's belief that the data contained in its New Drug Application (NDA) 22-481 support the conclusion that pixantrone is effective for its planned use. The Company stated that the OND requested additional analyses from the PIX301 phase III clinical study."

To read the entire report visit: www.microstockprofit.com/lp/CTIC

See what investors are saying about CTIC at http://www.stockhideout.com

Get breaking news on CTIC at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson
         info@microstockprofit.com
         1-888-307-2850

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 1.97%
$30K home equity loan FICO 5.80%
$75K home equity loan FICO 4.54%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.70%
13.70%
Cash Back Cards 17.91%
17.91%
Rewards Cards 17.17%
17.17%
Source: Bankrate.com